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a  b  s  t  r  a  c  t
Seasonal  inﬂuenza  is an  important  disease  which  results  in  250,000–500,000  annual  deaths  worldwide.
Global  targets  for  vaccination  coverage  rates  (VCRs)  in  high-risk  groups  are  at  least  75% in  adults  ≥65  years
and  increased  coverage  in  other risk groups.  The  International  Federation  of  Pharmaceutical  Manufactur-
ers  and  Associations  Inﬂuenza  Vaccine  Supply  (IFPMA  IVS)  International  Task  Force  developed  a survey
methodology  in  2008,  to assess  the  global  distribution  of  inﬂuenza  vaccine  doses  as a  proxy  for  VCRs.  This
paper updates  the  previous  survey  results  on  absolute  numbers  of  inﬂuenza  vaccine  doses  distributed
between  2004  and  2013  inclusive,  and  dose  distribution  rates  per  1000  population,  and provides  a qual-
itative  assessment  of  the principal  enablers  and  barriers  to  seasonal  inﬂuenza  vaccination.  The  two  main
ﬁndings  from  the quantitative  portion  of  the survey  are  the  continued  negative  trend  for  dose  distribution
in the EURO  region  and the  perpetuation  of  appreciable  differences  in  scale  of  dose  distribution  between
WHO  regions,  with  no observed  convergence  in  the  rates  of  doses distributed  per  1000  population  over
time.  The  main  ﬁndings  from  the qualitative  portion  of  the  survey  were  that  actively managing  the  vac-
cination  program  in real-time  and  ensuring  political  commitment  to  vaccination  are  important  enablers
of  vaccination,  whereas  insufﬁcient  access  to vaccination  and  lack  of  political  commitment  to  seasonal
inﬂuenza  vaccination  programs  are  likely  contributing  to vaccination  target  failures.  In all  regions  of  the
world,  seasonal  inﬂuenza  vaccination  is  underutilized  as  a public  health  tool.  The  survey  provides  evi-
dence of  lost  opportunity  to protect  populations  against  potentially  serious  inﬂuenza-associated  disease.
We call  on  the national  and  international  public  health  communities  to  re-evaluate  their  political  com-
mitment  to  the  prevention  of  the  annual  inﬂuenza  disease  burden  and  to develop  a systematic  approach
to  improve  vaccine  distribution  equitably.
© 2015  The  Authors.  Published  by Elsevier  Ltd. This  is an open  access  article  under  the  CC BY  license. Introduction
Seasonal inﬂuenza is an important disease which results in
50,000–500,000 annual deaths worldwide [1], of which about
8,000–111,500 are in children <5 years of age, predominantly
n developing countries [2]. Adults aged 65 years or older,
regnant women, and people of any age with underlying medical
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264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article u(http://creativecommons.org/licenses/by/4.0/).
conditions, are at high risk of severe disease or complications [1].
Licensed inﬂuenza vaccines are safe and efﬁcacious and are rec-
ommended by the World Health Organization (WHO) in priority
for pregnant women, children aged between 6 and 59 months, the
elderly, individuals with speciﬁc underlying medical conditions,
and health-care workers [2]. Some countries are progressively
expanding the recommended population, with the USA having
moved to routine vaccination of any individual >6 months of
age since 2010 [3]. Global targets for vaccination coverage rates
(VCRs) in high-risk groups are at least 75% in adults ≥65 years and
increased coverage in other risk groups [4]. Europe has set similar
targets [5]. In the US a 90% target has been set for adults ≥65 years
and 70% for persons ≥18 years, by 2020 [6].
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Globally, there are very limited data on inﬂuenza VCRs. Region-
lly, some seasonal inﬂuenza VCR data is available from PAHO
Pan-American Health Organization) for states in AMRO (region
f the WHO’s Americas Regional Ofﬁce) [7], and in Europe, data
s available for some states from the Vaccine European New
ntegrated Collaboration Effort (VENICE) [8]. The International
ederation of Pharmaceutical Manufacturers and Associations
nﬂuenza Vaccine Supply (IFPMA IVS) International Task Force
eveloped a survey methodology, in 2008, to assess the global
istribution of inﬂuenza vaccine doses [9]. Dose distribution can
erve as a proxy for VCRs where coverage data is lacking. The
FPMA IVS cumulated data on the distribution of vaccine doses
rom 2004 to 2011, in up to 157 countries [9–11]. Previous global
accine dose distribution surveys suggested that VCRs were sub-
tantially below target in all regions [10,11]. Three out of six WHO
egions together accounted for about 47% of the global popula-
ion but only about 4% of the IFPMA IVS doses distributed [10,11].
verall, global distribution of IFPMA IVS member vaccine doses
ncreased by approximately 87% between 2004 and 2011, but only
y approximately 12% between 2008 and 2011. Furthermore, dose
istribution decreased in EURO (region of the WHO’s European
egional Ofﬁce) and EMRO (region of the WHO’s Eastern Mediter-
anean Ofﬁce) between 2009 and 2011. The only countries to ever
eport achieving seasonal inﬂuenza VCR targets in the elderly are
he UK and the Netherlands [12,13], and no country has reported
arget VCRs in other risk groups [14,15], or in health care workers
16].
The aim of this paper is to update the results of the previ-
us surveys, to show the evolution in the number of inﬂuenza
accine doses distributed between 2004 and 2013 inclusive, in
bsolute numbers and in number of doses distributed per 1000
opulation, and to provide a qualitative assessment of the principal
nablers and barriers to seasonal inﬂuenza vaccination, as directly
xperienced by countries with a signiﬁcant rate of change in dose
istribution.
. Methods
.1. Quantitative vaccine dose distribution survey
The methodology used to survey dose distribution has been
reviously described in Palache et al., 2011 [10]. Brieﬂy, mem-
er companies of the IFPMA IVS (Abbott Biologicals, Adimmune
orporation, Biken, bioCSL, Janssen-Crucell, Denka Seiken, Glaxo-
mithKline Biologicals, Green Cross Corporation, Hualan Biological,
aketsuken, Kitasato Daiichi Sankyo Vaccine, MedImmune, Novar-
is Vaccines, and Diagnostics, Protein Sciences Corporation,
aint-Petersburg Scientiﬁc Research Institute of Vaccines and Sera,
anoﬁ Pasteur, Sinovac and Takeda), which manufacture and sup-
ly the vast majority of the world’s seasonal inﬂuenza vaccines,
greed to provide information on the supply of seasonal trivalent
nﬂuenza vaccine doses to all WHO  Member States during 2012 and
013. To ensure compliance with anti-trust regulations, the survey
esults were conﬁdentially collected and aggregated by the IFPMA
ecretariat. The resulting anonymized database was then combined
ith the results of the previous IFPMA IVS surveys (2004–2011)
9–11].
.1.1. Vaccine dose distribution in absolute numbers between
004 and 2013
Doses distributed by country and by year were aggregated and
hen, to facilitate comparisons, were categorized by distribution to
HO region.3 (2015) 5598–5605 5599
2.1.2. Vaccine dose distribution per population size between 2004
and 2013
To assess vaccine dose distribution in relation to each country’s
population size, the study utilized population data from the UN’s
(United Nations) statistics database [17]. Doses distributed to each
country were expressed per 1000 population for 2004–2013 using
the corresponding population ﬁgures from the United Nation’s
(UN) statistics database. To facilitate comparisons, countries were
then categorized by WHO  region. T-test analyses were performed
between rates of dose distribution/1000 population in 2004 and
2013, and 2008 and 2013, by WHO  region.
2.1.3. Rate of change in vaccine dose distribution between 2008
and 2013
To better understand the factors inﬂuencing seasonal inﬂuenza
vaccine dose distribution, countries were categorized into: previ-
ously low distribution (<159 doses per 1000 population, in 2008);
and, previously high distribution (≥159 doses per 1000 population,
in 2008). This ‘hurdle’ rate of 159 doses per 1000 population was
previously deﬁned as the number of doses required to vaccinate
those aged 65 years or older in industrialized nations [10], and
was again utilized to enable comparisons with previous surveys.
For each of the two categories of country (low distribution rate and
high distribution rate), the 10 countries with the highest increase in
dose distribution per 1000 population, and the 10 countries with
highest decrease in dose distribution per 1000 population, were
singled out for analyses.
2.2. Qualitative vaccine dose distribution survey
Descriptive analysis from selected countries with a change
in dose distribution rate of trivalent seasonal inﬂuenza vaccine
in the last 2 years of the dose distribution survey (2012 and
2013) was  collected through phone or e-mail interviews with
thought leaders or policy-makers, to determine speciﬁc policies
and practices associated with positive or negative trends in sea-
sonal inﬂuenza vaccination distribution. Questions were designed
to assess: national commitments to measure and increase vaccina-
tion coverage; implementation of recommendations, funding, and
communications; perception of inﬂuenza and VCR; country spe-
ciﬁc barriers or drivers for VCR; and lessons learnt in the delivery
of seasonal inﬂuenza vaccine.
A convenience sample of thought-leaders from seven countries
was selected, based on the trend of change in vaccine dose distri-
bution, and the ability of thought-leaders to inform on enabling
policies or barriers to inﬂuenza vaccine uptake. The four countries
with increasing distribution rates in the last 2 years of the sur-
vey invited to participate were: Thailand, Italy, Argentina, and
the UK. The three countries with decreasing distribution rates in
the last 2 years of the survey invited to participate were: the
Netherlands, Switzerland and the Republic of Korea. The selection
of countries was restricted to the three regions with the bulk of vac-
cine doses distribution (AMRO, EURO and WPRO) so that trends in
dose distribution in countries from these regions could be further
probed.
Persons invited to participate included: a director of a depart-
ment of infectious, parasitic and immune mediated diseases, at a
national public health institute; a director of a national institute
of immunization in a ministry of health; the CEO of a consortium
between a government and vaccine industry; a Director General
at a national ministry of health; the head of a federal commis-
sion on vaccination; the head of a national division of vaccine
preventable disease control and national immunization program;
and a former director of immunization at a national Department of
Health.
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Fig. 1. Seasonal inﬂuenza vaccine dose distribution by region.
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. Findings
.1. Quantitative vaccine dose distribution survey results
There has been an 87% increase in the total number of IFPMA
VS doses of seasonal inﬂuenza vaccine distributed between 2004
nd 2013 (from approximately 262–490 million), with variation
y WHO  region (Fig. 1). In EURO, the increase in number of doses
istributed between 2004 and 2013 was 9.6%, but it decreased by
1.5% between 2008 and 2013.
The number of IFPMA IVS doses distributed per 1000 population
n each WHO  region is shown in Fig. 2. A country-by-country break-
own is shown for AMRO and EURO in Figs. 3 and 4. Between 2004
nd 2013, there was a signiﬁcant increase in the number of doses
istributed per 1000 population in AMRO (T-test, p = 0.01) and the
ombined regions of AFRO (region of the WHO’s African Regional doses distributed per 1000.
Ofﬁce), AMRO and SEARO (region of the WHO’s Southeast Asian
Regional Ofﬁce) (T-test, p = 0.02), but not in EURO or WPRO (region
of the WHO’s Western Paciﬁc Regional Ofﬁce). Between 2008 and
2013, the only signiﬁcant change in doses distribution was in EURO,
where a signiﬁcant decrease occurred (T-test, p = 0.04).
Based on the hurdle rate of <159 doses per 1000 population, 166
of the 195 countries were classiﬁed as low-distribution in 2008.
There were no doses distributed in 52 (31%) countries in either
2008 or 2013 and in the 114 countries with some dose distribution,
66 (58%) had an increase in the number of doses distributed per
1000 population between 2008 and 2013. Out of the 29 countries
classiﬁed as high-distribution in 2008, only 7 (24%) increased
the numbers of doses distributed per 1000 population between
2008 and 2013. High distribution countries with an increase in
the number of doses distributed per 1000 population in 2013
were either from the AMRO or WPRO regions. Eighteen out of the
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Fig. 3. Inﬂuenza vaccine doses distributed per 1000 in AMRO.
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1 high-distribution countries (86%) that had a decrease in num-
ers of doses distributed per 1000 population between 2008 and
013 were from the EURO region.
In previous IFPMA IVS surveys [10,11], change in distribution of
oses per 1000 population was not correlated with country income.
owever, in 2013, greater number of doses distributed per 1000
opulation were moderately correlated with higher Gross National
ncome in AMRO, WPRO, and SEARO: r = 0.69, 0.64, and 0.65 respec-
ively..2. Qualitative vaccine dose distribution survey results
A total of 6 thought leaders from ﬁve countries accepted to
articipate in the qualitative survey: individuals from Italy (n = 1),201320122011201020092008
tributed per 1000 in EURO.
Netherlands (n = 1), Thailand (n = 1), Republic of Korea (n = 2), and
the UK (n = 1). Italy, Thailand, and the UK participated by telephone
interview. The thought leader from the Netherlands responded in
writing, The thought leaders from the Republic of Korea responded
in writing and participated by telephone interview.
The Netherlands, Italy, and UK had important increases in dose
distribution in the 2008/2009 and 2009/2010 inﬂuenza seasons,
most likely because of the heightened public and provider aware-
ness associated with the 2009 H1N1 pandemic. However, since
2010, the Netherlands and Italy have an overall downward trend in
dose distribution, with Italy rebounding slightly between 2012 and.
2013. The distribution in the UK suggests a constant upward trend
in non-pandemic inﬂuenza seasons, since 2004, with the drop in
distribution in 2010 most likely to be a data artifact. Thailand and
5602 A. Palache et al. / Vaccine 33 (2015) 5598–5605
Table 1
Summary of policies that enable seasonal inﬂuenza vaccine uptake, as described in the qualitative assessment interviews.
Policies that enable seasonal inﬂuenza vaccination
Category Sub-category Description
Vaccine advocacy and
education
For the general public Media campaigns, including with or without high proﬁle public ﬁgures, targeted at educating the
public on the risks of the disease and the risks and beneﬁts of vaccination
For  the elderly Directed at the elderly
For high risk groups Directed speciﬁcally to high-risk target groups (COPD, heart disease, etc.)
For  vaccinators Directed at vaccinators such as through reminder letters, expert training, conferences, university
lectures
Education on the risk and beneﬁts of seasonal inﬂuenza directed at vaccinators
Education directed at vaccinators on how to raise vaccination coverage
Building public trust Monitoring of adverse events following
vaccination
Rapid investigation by authorities of reports of adverse events following seasonal inﬂuenza
vaccination
Communications to the general public Rapid and transparent communication on adverse events following seasonal inﬂuenza
vaccination; communicating on the incidence of disease and the public health impacts
Disease surveillance Monitoring seasonal inﬂuenza incidence and the public health and economic impacts
Evaluation of vaccination program
impact
Communicating to on the impacts of the vaccination program
Real-time management
of the vaccination
program
Monitoring vaccination coverage in
real time
Communicating in real-time on vaccination coverage/vaccine distribution for the purpose of
vaccination performance management
Taking necessary actions, in real-time,
to improve vaccination performance
Using real-time vaccination coverage to identify and correct issues related to vaccination coverage
(supply issues, access issues, communication issues, etc.)
Political commitment Prioritizing inﬂuenza within the health
portfolio
Obtaining a political commitment to emphasize the importance of seasonal inﬂuenza vaccination
Improving access to
vaccination
Increase delivery points Provide access to vaccine at many/all public of private health care facilities
Reduce restrictions to access Eliminate restrictions such as location of residence to access delivery points
Eliminate/reduce payment for
vaccination
Provide vaccination at no out-of-pocket expense to vaccinees
Re-consider age limits for vaccination Increase vaccination coverage by lowering age of vaccination for the elderly
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Provide monetary incentives to
vaccinators
Compensate
he Republic of Korea have overall upward trends in dose distri-
ution since 2008, but there has been a considerable decline in
orea between 2012 and 2013. Korea’s highest rate of distribution
ere preceding and following the pandemic years (2009 and 2010)
eclining between 2004 and 2009, although overall rates were high
n any given year. In Thailand, the rates of distribution were higher
n 2012 and 2013 than in 2009 and 2010. Therefore the impact of the
1N1 pandemic on vaccine doses distribution is likely to be highly
ontextual. For instance, a downward trend in the Netherlands after
he pandemic years, but an overall upward trend in the UK since
004, can be attributed to differences in the application of poli-
ies. An attitude that favors individual choice over public pressure
o get vaccinated may  explain the differences in trends between
hese two countries.
The main enabling policies identiﬁed in the interviews are
hown in Table 1. Enabling factors were categorized thematically
nd can be summarized as promotion of vaccination, building pub-
ic trust, actively managing the vaccination program in real-time,
nsuring political commitment to vaccination, and enabling better
ccess to vaccination (including limiting or eliminating out-of-
ocket expenses).
The main barriers identiﬁed are shown in Table 2. They include
ack of public demand, lack of public conﬁdence, insufﬁcient access
o vaccination, lack of political commitment to seasonal inﬂuenza
accination programs, deﬁcient programs, and lack of education for
accinators.
The key identiﬁed contributors to vaccination target failures
ere political commitment to seasonal inﬂuenza vaccination,
hich is variable between countries (with some countries still
esitating to implement corrective measures to reach vaccina-
ion targets), and poor program performance (such as failure to
onitor vaccination coverage and take corrective actions in real
ime). Political support was linked to real time management where
oth disease outbreaks and vaccination coverage were being usednators for vaccination
to take corrective measures and to demonstrate the impacts of
vaccination.
Real-time management of the seasonal inﬂuenza vaccination
programs (monitoring of vaccination coverage and implementation
of corrective actions, and weekly disease surveillance) was  cited
as critical for achieving vaccination coverage targets. Electronic
records of vaccination enable real time analyses of vaccination cov-
erage by age and risk group, which is then communicated directly
to vaccination providers.
Both enablers and barriers were consistently identiﬁed by
countries regardless of their classiﬁcation as increasing or declining
countries.
4. Discussion
The two main quantitative ﬁndings from this survey are: a con-
tinued negative trend for dose distribution in the EURO region; and,
the continued appreciable differences in scale of dose distribution
between WHO  regions, with no observed convergence in the num-
ber of doses distributed per 1000 population over time. The rate of
growth in seasonal inﬂuenza vaccine dose distribution has dramat-
ically slowed since 2008, with only an approximate 12% increase in
number of doses distributed between 2008 and 2013 (436 and 490
million doses respectively) and only 39% of countries (76 out of
196) having increased the number of doses distributed per 1000
population over the same time period. In 2013, only 21 out of 196
countries (11%) had achieved or surpassed the hurdle rate of 159
doses per 1000 population.
This coincides with a concurrent global economic downturn, but
the slowed rate of growth in the distribution of vaccine doses is
unlikely to be related to economic woes, since we  could ﬁnd no
strong correlations between vaccine dose distribution and national
wealth (GNI), consistent with previous ﬁndings [10,11].
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Table  2
Summary of barriers to seasonal inﬂuenza vaccine uptake, as described in the qualitative assessment interviews.
Factors identiﬁed as obstacles to vaccine uptake
Category Sub-category Description
Lack of public demand Perception of low risk from inﬂuenza Inﬂuenza not associated with severe consequences (health or ﬁnancial)
Risk  groups do not identify as being at
high-risk
Risk groups fail to associate an increased risk from inﬂuenza with their underlying conditions
Lack  of public
conﬁdence
Doubt or lack of evidence of vaccine
effectiveness
Inﬂuenza vaccination is perceived as poorly effective.
Data on vaccine effectiveness not available for all countries
Mistrust of government Public perception that vaccination policies are set for motives other than public health
Negative fallout from H1N1 pandemic Perception of government over-reaction to the H1N1 pandemic.
Fear of rare adverse events associated with pandemic H1N1 vaccines
Fear of adverse reactions from
vaccination
Perception of link between seasonal inﬂuenza vaccination and severe adverse events/deaths.
Fears generated by media attention on some quality issues with vaccine
Low  seasonal inﬂuenza vaccination
coverage in health care workers
Low vaccination coverage in health care workers lowers public conﬁdence in vaccine
Challenges with access
to vaccination
Access not facilitated for high risk
groups
Lack of special vaccine delivery points for high-risk groups may  limit access
Supply management deﬁciencies Issues with timely supply of vaccine due to quality issues (vaccine recalls) or other supply
management issues
Lack of vaccinator motivation Vaccinators not always adept/motivated to counsel for vaccination
Lack  of political
commitment
Low priority of inﬂuenza Other disease may be given priority over inﬂuenza within the health portfolio, especially in
tropical settings where other infectious disease are prevalent
Inﬂuenza vaccination
program deﬁciencies
Failure to monitor disease and
vaccination coverage in real time
Without information of vaccination coverage and disease incidence in real-time, corrective action
cannot be taken to limit spread of disease and increase vaccination coverage where needed
Vaccination coverage for speciﬁc
targets not monitored because
denominators are unknown
Without coverage data, impacts of vaccination cannot be assessed and used to inform the program
Emphasis on individual choice May  undermine the public health objectives of high vaccination coverage
Low cost-effectiveness of targeting
small risk groups
Some risk groups may be small in number and require disproportionate efforts to access
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Insufﬁcient training on vaccination Vaccination
In addition to the global stagnation in rates of doses distributed,
here are important regional disparities. The rates of distribution in
URO and WPRO represent only 39% and 21%, respectively of the
ate in AMRO, in 2013. SEARO, EMRO and AFRO show an insigniﬁ-
ant distribution. This, in itself, suggests that a major global review
f tactics to achieve seasonal inﬂuenza vaccination targets is warr-
nted. Important lessons may  be learned from the experiences and
olicies, from countries that have consistently increased vaccine
tilization over time, such as the UK. The qualitative survey indi-
ates that real-time management of the vaccination program is
ritical for demonstrating the impact of the program and in turn
enerating the political support to sustain and grow the program.
his was reported by the UK, but countries other than the UK
ay  also use real-time data for the management of their inﬂuenza
rograms to some degree. This is also a key learning from the man-
gement of the H1N1 pandemic in the US [18].
AMRO continues to dominate the rate of dose distribution
Fig. 2), where growth is driven by countries that initially had
ery little distribution. However, improving on already high dose
istribution rates is particularly challenging as can be seen from
he US and Canada, where distribution rates may  have plateaued
Fig. 3).
Growth in the dose distribution rate in WPRO rose by 71%
etween 2004 and 2013, but only by 27% between 2008 and 2013.
he scale of distribution in this region pales in comparison with
MRO: 58 versus 278 doses per 1000 population in 2013, respec-
ively.
In EURO (Fig. 4), only 11 of 53 countries (21%) had increased rates
f doses distributed between 2008 and 2013, and the distribution
ate in 2013 was 35% lower than the peak distribution in 2009. Rates
f distribution fell in 38 out of 53 (72%) countries between 2008 and
013. What’s more, EURO was the only region that experienced a
ecreased rate of distribution during this period, with the drop in
ate being statistically signiﬁcant. Given these ﬁndings, and based
n the tactics to achieve goals laid out in the EU Council recommen-
ations [19], national and international public health communitiesrominent and sometime marginal in medical training curricula
may  well need to re-evaluate their political commitment to the
prevention of the annual inﬂuenza disease burden.
On the whole, the quantitative survey found that in all regions
of the world, seasonal inﬂuenza vaccination is underutilized as a
public health tool. Globally, the WHO’s targets for inﬂuenza con-
trol [20] are not being achieved. There is an important cause for
concern, with evidence of slowed expansion of vaccine distribu-
tion and, more importantly, evidence of reduced distribution in
42% of countries globally, between 2008 and 2013. In Europe,
72% of countries had lower dose distribution rates in 2013 than
in 2008.
The barriers identiﬁed by the qualitative survey have known
corrective actions which are regularly implemented in countries
with successful programs. However, the survey identiﬁed that in
at least one country the underlying cause of program deﬁciencies
may  be a lack of political commitment to seasonal inﬂuenza vac-
cination. Real time management of the vaccination program will
help to secure political commitment by demonstrating the impact
of the disease and of vaccination.
When policy enablers are implemented independently of each
other, they are unlikely to be impactful. The qualitative survey iden-
tiﬁed cases where some, but not all, enablers were utilized, for
instance communication to the public but no real-time monitoring
of vaccination coverage.
One of the most important ﬁndings from the qualitative sur-
vey was an emphasis on active management of the vaccination
program. This was  identiﬁed as the key enabler by countries that
practice real-time management and also recognized as a deﬁciency
by countries which do not. The active monitoring of vaccination
coverage and the real-time identiﬁcation of solutions tailored to
speciﬁc coverage issues were deemed critical for meeting pro-
gram targets. It is not a coincidence that the UK, which enjoys
the highest vaccination coverage amongst European states, man-
ages its program in real-time and attracts the highest of political
commitments. Clearly, a combination of active management and
political commitment are fundamental to a successful vaccination
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rogram. Furthermore, the often used argument of vaccine effec-
iveness has not dissuaded political commitment to vaccination in
he UK, even though the UK uses the same vaccines as elsewhere
n Europe.
There is considerable stagnation in seasonal inﬂuenza vacci-
ation coverage and a lack of interest or motivation in speciﬁc
ountries in all WHO  regions, and in EURO as a whole. This is in spite
f the strong scientiﬁc evidence-based consensus about the impact
f the disease and the beneﬁts of vaccination [21,22], the unequiv-
cal international recommendations from WHO  [2] as well as the
ecommendations for universal seasonal inﬂuenza vaccination in
arious countries [23].
The surveys highlight a lag in implementing both interna-
ional and national recommendations by public health authorities
n several countries. This may  well have resulted in a signiﬁ-
ant vaccine-preventable burden from inﬂuenza disease. In Europe
lone, un-prevented inﬂuenza has been estimated at 1.6–1.7 mil-
ion cases annually [15]. A French study estimated the total cost of
nﬂuenza at more than 1796 million D each year [24]. In the United
tates, the yearly total costs (direct and indirect) of an inﬂuenza
pidemic have been calculated at approximately D10,000–17,000
illion. In some settings as little as 40% of health care professionals
HCPs) are immunized against inﬂuenza [25] even though vacci-
ation could reduce mortality among their patients by up to 44%
26].
In Europe, a lack of public conﬁdence in the reaction to the
1N1 pandemic in 2009, including poor communication to stake-
olders, confusion between reported adverse events (narcolepsy)
rom an adjuvanted pandemic vaccine [27–30] and non-adjuvanted
easonal inﬂuenza vaccines, have likely contributed to the contrac-
ion of vaccine uptake. A more pragmatic approach to inﬂuenza
accination might, therefore, be considered in Europe. The US, for
nstance, has opted to recommend inﬂuenza vaccination in all age
roups since 2010 [3] with a relatively constant number of doses
istributed per capita since 2007. To some extent, this policy may
lso protect from the backlash against inﬂuenza vaccination seen in
ost-H1N1 Europe, as inﬂuenza vaccination increasingly becomes
art of the social norm.
In addition to the considerable economic and social impacts
rom an un-prevented burden of disease, consensus groups have
lso highlighted the risks to pandemic preparedness from poor sea-
onal inﬂuenza vaccine delivery [21,22]. Since the infrastructure
or seasonal inﬂuenza vaccination is ultimately the usable infra-
tructure for a response to an inﬂuenza pandemic, the surveys also
ighlight a public health failure to adequately prepare for and man-
ge a next inﬂuenza pandemic.
The limitations of our quantitative ﬁndings include some likely
rror in the reporting of numbers of doses by each vaccine dis-
ributor, but the uniform compilation of data from a standardized
lobal source, representing approximately 79% of the global sea-
onal inﬂuenza vaccine production [31], means that the impact
f any error should be minimal. We  acknowledge that in a few
ountries dose distribution may  not accurately reﬂect vaccination
overage. And dose distribution in countries that are supplied pri-
arily by non-IVS members [31] like India and China (with 12
ocal inﬂuenza vaccine manufacturers), may  be underrepresented.
n EURO, however, all doses are sourced from IFPMA IVS members
32]. In spite of these limitations, the IFPMA IVS dose distribution
ata reasonably represents vaccine utilization in the WHO  regions,
nd shows temporal evolution.
We  also acknowledge that the ‘hurdle’ rate was  developed for
he purpose of having a single comparator to facilitate comparisons
etween all countries within and between WHO  regions, but may
ot be representative of the actual number of doses required to
accinate those aged 65 years or older in developing nations (where
opulations may  be younger on the whole).3 (2015) 5598–5605
For our qualitative ﬁndings, we  acknowledge that the sampling
of countries was  minimal and may  not be representative. As previ-
ously noted, enablers and barriers of vaccination may  be contextual
and unique to individual countries. However, there was a high
degree of concordance in the responses elicited which suggests that
a larger sample size may  not signiﬁcantly alter our ﬁndings.
5. Recommendation
The IFPMA IVS survey provides important data on the dose dis-
tribution trends in the different WHO  regions. The current IFPMA
IVS dose distribution survey, corroborates the ﬁndings of the pre-
vious surveys [10,11], and ﬁnds that dose distribution in EURO
is declining with 72% of countries distributing fewer doses of
inﬂuenza vaccine in 2013 than in 2008. Globally, in 2013, 89% of
countries had not achieved the hurdle rate of 159 doses distributed
per 1000 population.
These trends have been monitored since 2004 and high-
light a potentially serious public health failure to implement
international recommendations and achieve vaccination targets.
Given the global scale of these shortcomings, we believe it is time
for strong and immediate policy actions to address the slow or
absent progress toward meeting the seasonal inﬂuenza vaccination
coverage targets. We  call on the national and international pub-
lic health communities to re-evaluate their political commitment
in prevention of the annual inﬂuenza disease burden. Internation-
ally mandated agencies, like WHO, have a critical role to play in
ensuring that international disease control targets are set and mon-
itored, but national health agencies and professional associations
must assume responsibility for the implementation and success or
failures of control programs. In addition, we encourage national
departments of health and medical leaders to develop a systematic
approach to improve vaccine distribution equitably across regions
in order to facilitate a tangible reversal of the negative trend and to
increase the probability to meet the VCR targets.
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